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Abstract
Introduction: It is increasingly important to prioritize the most cost-effective HIV interventions. We sought to summarize the
evidence on which types of interventions provide the best value for money in regions with concentrated HIV epidemics.
Methods: We conducted a systematic review of peer-reviewed and grey literature reporting measurements of cost-effectiveness
or cost-benefit for HIV/AIDS interventions in Asia and Eastern Europe.We also collated HIV/AIDS spending assessment data from
case-study countries in the region.
Results: We identified 91 studies for inclusion, 47 of which were from peer-reviewed journals. Generally, in concentrated
settings, prevention of mother-to-child transmission programmes and prevention programmes targeting people who inject drugs
and sex workers had lower incremental cost-effectiveness ratios than programmes aimed at the general population. The few
studies evaluating programmes targeting men who have sex with men indicate moderate cost-effectiveness. Collation of
prevention programme spending data from 12 countries in the region (none of which had generalized epidemics) indicated that
resources for the general population/non-targeted was greater than 30% for eight countries and greater than 50% for five
countries.
Conclusions: There is a misalignment between national spending on HIV/AIDS responses and the most affected populations
across the region. In concentrated epidemics, scarce funding should be directed more towards most-at-risk populations.
Reaching consensus on general principles of cost-effectiveness of programmes by epidemic settings is difficult due to
inconsistent evaluation approaches. Adopting a standard costing, impact evaluation, benefits calculation, analysis and reporting
framework would enable cross comparisons and improve HIV resource prioritization and allocation.
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cost-effectiveness.
To access the supplementary material to this article please see Supplementary Files under Article Tools online.
Received 30 July 2013; Accepted 17 January 2014; Published 25 February 2014
Copyright:– 2014 Craig AP et al; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution
3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
Introduction
Asia is the second most HIV-affected region of the world and
Eastern Europe is the only region of the world in which HIV
epidemics continue to increase [1]. These regions are not
only geographically adjacent but share similar HIV epidemic
features. HIV epidemics in Asia and Eastern Europe are
concentrated among most-at-risk populations (MARPs), spe-
cifically among people who inject drugs (PWID) and sex
workers (SW) and more recently in some countries also
among men who have sex with men (MSM) [1].
Although responses to HIV epidemics in these regions have
increased over the past decade, they have not controlled
the spread of infection due to an inadequate coverage of
populations most at risk. The increased response to HIV
epidemics is largely due to substantial bilateral and multi-
lateral donor investment in low- and middle-income coun-
tries across the region [2]. However, it is acknowledged that
as this investment is withdrawing [3] it is becoming in-
creasingly important to get more value for the available HIV
money by prioritizing the most cost-effective HIV interven-
tions. Allocating resources in the most effective way will
reduce new infections and the morbidity and mortality
caused by HIV.
HIV/AIDS intervention effectiveness evaluation and cost-
effectiveness studies have become important analytical tools
to understand what HIV investments have bought and which
future allocation of funds is likeliest to result in the greatest
epidemiological impact. The most comprehensive review of
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the cost-effectiveness of HIV programmes we identified was
by Pattanaphesaj and Teerawattanon [4], who reviewed evi-
dence specific for Thailand between 1997 and 2008. More
specific reviews included Wolfe et al. [5], which reviewed the
cost-effectiveness evidence of antiretroviral therapy (ART)
for PWID, focusing on low- and middle-income countries.
Galárraga et al. [6] reviewed relevant literature published in
the years 20052008 for low- and middle-income countries
and Sweeney et al. [7] considered studies that investigated
the integration of HIV and AIDS services with other health
services. Although these studies are not an exhaustive list of
HIV cost-effectiveness reviews, the purview of recent broad-
ranging reviews does end at 2008, reviews of subsequent
periods concentrate on particular intervention types and
we have not identified any reviews of all intervention types
across a global region.
We conducted a systematic review of cost-effectiveness
studies of HIV/AIDS programmes across Asia and Eastern
Europe in order to identify evidence for which type of inter-
ventions offer the best value-for-money to address HIV
epidemics in this region. To our knowledge, the current study
is the broadest such review yet conducted. We also review
National AIDS Spending Assessments from 12 case-study
countries across the region to ascertain to what extent pre-
vention spending is aligned with cost-effectiveness evidence.
Methods
The criteria for a study to be included in the review were that
the study considered an intervention to prevent HIV infection
or reduce the burden of HIV, either in terms of health (as
quantified by e.g. quality adjusted life-years (QALYs)) or in
financial/economic terms; that the intervention occurred in
Asia or Eastern Europe, or, if amalgamated results for a group
of regions were presented, that a majority of the regions in
the group were in Asia or Eastern Europe; and that the study
reported at least one of the following: (1) cost per HIV
infection averted, cost per disability adjusted life-year (DALY)
averted, cost per QALY gained, cost per life-year saved or
information that allowed simple calculation to produce one
of these indicators; or (2) cost at which an intervention would
be deemed cost-effective; or (3) cost savings; or (4) net pres-
ent value, rate of return, or benefit-cost ratio. Our inclusion
criteria meant that we included cost-effectiveness analyses
(CEA), cost-benefit analyses (CBA) and cost-utility analyses
(CUA), as well as other kinds of economic evaluation.
We searched the following databases: PubMed, EMBASE,
LocatorPlus, EconLit, Tufts Medical Center CEA Registry.
We also searched the World Bank Documents & Reports
database, as well as those of the Asian Development Bank,
UNAIDS, the Department for International Development UK,
the International AIDS Vaccine Initiative, the International
Partnership for Microbicides, the Office of Health Economics
UK and PEPFAR. We also conducted Google searches on
individuals known to have produced relevant papers or re-
ports, models known to be used in HIV CEA and on each of
the countries considered (the large numbers of results for
these Google searches meant that checking each individually
would have been prohibitively time-consuming: as such, we
chose to check the first 100 results of each query). We
adjusted the list of search keywords according to the cap-
abilities of each search engine, but we required a match for a
keyword synonymous with ‘‘HIV’’ or ‘‘AIDS,’’ and a keyword
similar in meaning to ‘‘cost-effectiveness’’ or ‘‘programme
evaluation.’’ We have provided the full list of search strings,
the dates on which they were conducted and the number of
hits (Supplementary file 1).
We also searched the references of identified studies and
included referenced documents if they met our inclusion
criteria. In addition, we included any relevant documents
that we encountered for any reason during the course of the
review. In several cases contacting an author with a request
for further information also yielded documents that were
considered for inclusion. Where evaluations in multiple stu-
dies considered the same intervention and were all con-
ducted before the intervention or all conducted during/after
the intervention, we chose one study for inclusion on the
basis of comprehensiveness and publication date.
To better enable comparison of results from disparate
countries and years we converted all incremental cost-
effectiveness ratio (ICER) results into 2011 US$. Where ICERs
were given in a non-US currency we converted the ratios into
US$ for the same year, by dividing by the US per capita gross
domestic product (GDP) purchasing power parity (PPP) and
multiplying by the per capita GDP PPP corresponding to
the non-US currency used. Per capita GDP PPP measures
the value of goods produced in a country relative to the in-
country purchasing power of that country’s currency. By
using PPP instead of the exchange rate to do the conversion
from local currency to US$ we estimate the number of US$
that would buy similar goods in the United States as could be
bought in the original country with the amount of local
currency to be converted. Under this approach, when ICERs
were given in a non-US currency that was also not the
currency of the country in which the intervention took place,
the conversion used the per capita GDP PPP corresponding to
the country of the currency rather than the country of the
intervention. Per capita GDP PPP were sourced from the
International Monetary Fund [8] (Taiwan) and World Bank [9]
(all others); the World Bank figures did not include per capita
GDP PPP for 2012, so for those we used the correspond-
ing 2011 values. We then inflated that value into 2011 US$
using medical care consumer price indexes taken from the
United States Department of Labor [10]. In many cases, a
study provided only US$ or international dollar ICERs; in
these cases we skipped the currency conversion step.
When recording ICERs, we included ranges if these were
noted alongside or in place of point estimates. We excluded
ranges if they were noted in a separate sensitivity/uncer-
tainty analysis section. Some studies that reported ICERs for a
number of different interventions also calculated the ICERs
of combinations of these interventions; in these cases, we
reported only the ICERs for the separated interventions.
We standardized outcomes of studies for visualization and
comparison purposes. Considering the World Health Organi-
zation (WHO)-CHOICE criteria for cost-effectiveness thresh-
olds compare ICERs to a country’s GDP [11], we divide the
2011 US$ ICERs by the 2011 per capita GDP (nominal) of
the country in which the intervention was performed to
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normalize results. We used per capita GDP from [12] for
Taiwan and [13] for all others. No per capita GDP values were
available for the regions considered in studies that presented
multi-country amalgamated results, and so these were not
standardized for inclusion in figures.
We calculated summary statistics for the cost per HIV-
infection-averted ICERs (in 2011 US$). To calculate these, we
used the point estimates where available; where unavailable,
we took the mean of the lower and upper bounds. For those
studies in which ICER was recorded as ‘‘Cost-saving,’’ we
treated the ICER as 0 (although the true ICER would have
been negative).
We conducted a simple quality assessment of the included
studies, using a slightly modified version of Neumann et al.’s
checklist [14]. As part of this we calculated a ‘‘checklist
success score’’ for each study: this was the percentage of
non-N/A checklist items for which the result was not ‘‘no’’ or
‘‘unclear.’’
In order to compare actual spending patterns to our
findings on which populations can be targeted with HIV
interventions in a cost-effective manner, we estimated for 12
countries the proportion of resources allocated to prevention
programmes for SW/clients, MSM, PWID and the general
population, using HIV spending and budgeting data [1541]
and communication with in-country stakeholders. Pro-
grammes without a clear priority population were designated
as ‘‘Not targeted.’’ We excluded indirect costs including
overhead or management costs and health infrastructure
costs. Proportions allocated to each group were estimated
from available spending data over the period 20072011. No
adjustment for inflation was made.
Results
A flowchart of identified relevant studies and inclusions/
exclusions according to different criteria is presented in
Figure 1.
We included 91 studies (refs. 42129 and J. Stover, per-
sonal communication, August 16, 2012; J. Bottcher, personal
communication, August 17, 2012; D.P. Wilson, personal
communication, November 28, 2012); these studies are
summarized in a table (Supplementary file 3). Of the studies
included, 47 were peer-reviewed journal publications. There
were 28 countries considered individually; 9 studies gave
amalgamated results for groups of countries. The country
represented in the most studies was Thailand (21 studies),
followed by India (16 studies) and Ukraine (7 studies). Of
the 91 studies, 64 considered a single country/region and
primary target group; the remainder compared multiple
Records identified through primary database search
(EconLit: 46, EMBASE: 308, PubMed: 1554; Tufts: 2)
(N = 1910)  
Records removed after screening of titles
(N = 1311, including 44 removed as duplicates)
Abstracts screened
(N = 599)
Records excluded after screening of abstracts
(N = 515, including 15 that could not be found)
Full-text articles assessed for eligibility
(N = 84)
Full-text articles excluded, with reasons
(N = 55)
Could not access full text: N = 5 
Does not calculate relevant indicator:  N = 26 
Does not consider an intervention:  N = 5 
Does not explicitly consider relevant region:  N = 6 
Full text not English: N = 1 
Not concerned with HIV: N = 4 
Reports results of other study(s): N = 3
Study design: N = 2 
Duplicates another study:  N = 3 
Included in review
(N = 29)
Found in grey literature search or subsequently and
included in review
(N = 58)    


























Figure 1. Flowchart indicating inclusion and exclusion of studies (with numbers of studies N) at each stage of the review process.
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regions and/or primary target groups. The number of
included studies, by region/country and primary target group
of intervention(s) evaluated, is summarized in Table 1.
We included programme evaluations of future/hypothe-
tical interventions, as well as programme evaluations of in-
progress/completed interventions: there were 65 of the
former, 32 of the latter and 2 for which this was unclear.
Eight studies included both before and after analyses. (Some
studies considered in-progress or completed programmes,
but analyzed cost-effectiveness for extensions or expansions
of those programmes; we considered such evaluations to
be future/hypothetical.) Of the evaluations of in-progress/
Table 1. Counts of studies reporting at least one intervention of given combination of region and primary target group
Primary target group
Region PWID HIV MSM PMTCT
General















Cambodia 2 1 2 3
Indonesia 3 1 1 1 2
Papua New Guinea 1 1 1 2
Philippines 1
Singapore 1
Thailand 2 8 3 6 10 2 5 1
Timor Leste 1 1 1
Vietnam 1 1 1 1
Southeast Asia Region B 1













Russia 1 1 1 1
Ukraine 3 3 1 1 1
Multiple, Eastern Europe 1
Other
Multiple, Asia 2 1 2 1 1
Multiple, other 1 1 1 1 1 1 1
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completed studies, one assessed a randomized controlled
trial [59], one compared patient outcomes before and after
the introduction of highly active ART [81] and one compared
different arms of an observational cohort [74]; the rest
estimated effectiveness using approaches such as mathema-
tical modelling.
Cost per HIV infection averted was the most-reported of
the indicators we considered: 45 of the 91 studies gave at
least one value for this indicator, for a total of 194 values
with a mean of US$187,248, population standard deviation
US$899,973, minimum cost-saving, first quartile US$567,
median US$2,362, third quartile US$18,028 and maximum
US$10,687,255.
Peer-reviewed journal publications performed better in
the quality assessment (Supplementary file 2), with the mean
checklist success score for peer-reviewed journal publications
being 61% versus 32% for other studies.
Only one of the studies of an in-progress/completed inter-
vention clearly stated that it was an evaluation planned from
the outset, although many other evaluations were presum-
ably in the same category even if they did not make that
explicit. Of the studies of future/hypothetical interventions,
10 were clearly programme evaluations carried out during
their planning phases*all were either World Bank or Asian
Development Bank publications. A feasibility assessment by
the WHO also could be added to that number.
We noted whether studies of in-progress/completed inter-
ventions used prevalence or incidence routine surveillance
data in determining effectiveness; there were only two
studies where the answer was an unequivocal yes. In the
remaining cases, it was considered that the studies had not
used such data, or that they were not clear on this point;
however, many studies used mathematical models and it is
possible that surveillance data were used for calibration
without this being stated in the study.
Of the 32 studies that evaluated in-progress/completed
interventions, in five cases the source of the cost data used
was unclear. In each of the other 27 cases cost data were
drawn from actual costs and/or other sources, although
where these were not available costs were assumed.
The cost-effectiveness of HIV interventions varied substan-
tially across the Asia/Eastern Europe region. A comparison of
ratio estimates of ICERs/per capita GDP for all identified
evaluated interventions is provided in Figure 2.
Many studies gave ICERs for a single programme incorpor-
ating a number of interventions. Therefore, results are dif-
ferentiated by programme primary target group rather than
by intervention type. Whether results are presented accord-
ing to incremental cost per (a) life-year gained, (b) DALY
saved, (c) QALY gained or (d) HIV infection averted, inter-
ventions appear to range from less than one per capita GDP
to greater than 5 per capita GDP (Figure 2). Although there is
variation in cost-effectiveness ratios for all targeted popula-
tion group interventions, broadly it is identified that preven-
tion of mother-to-child transmission (PMTCT) interventions
and interventions targeted at PWID and SW/clients seem to
have lower ICERs/per capita GDP, while programmes that
were non-targeted or for the general population seem to
have greater ICERs/per capita GDP (Figure 2). Relatively few
studies focused on evaluating programmes targeting MSM. It
is also important to note that there were large differences
between studies in methodologies for assessing impacts and
estimating costs (e.g. some studies considered only the unit
costs of the intervention project, while others included
infrastructure costs, while still others also included averted
health care costs). This means that direct comparison of
results across studies must be done with caution. Of parti-
cular importance is the large difference in time horizons
considered in the included studies for assessment of ben-
efits, which ranged from one year to lifetime. Some studies
included the costs of health care while other studies did not.
The most common form of annual discounting used was 3%
for both costs and benefits, but this was not universal and
there were studies in which costs and/or benefits were not
discounted. Methods for estimating the burden avoided by
the intervention evaluated varied from dynamic mathema-
tical models to a simple assumption of the percentage of
infections averted [51].
Of the 91 studies, 51 indicated whether or not the
interventions studied were considered cost-effective and/or
cost-saving, and 2 studies indicated costs at which the
interventions would be considered cost-effective, based on
HIV mobility [53] or vaccine costs [112]. No study reported
that none of the interventions considered were cost-effective,
although in many cases statements of cost-effectiveness
were qualified with epidemic condition thresholds that
would be necessary for the intervention to be cost-effective
(e.g. [98]). The threshold or comparator for establishing cost-
effectiveness varied:most used theWHO’s standard,with inter-
ventions with a cost-effectiveness of less than the per capita
GDP considered highly cost-effective, and those with a cost-
effectiveness of between one and three times the per capita
GDP considered cost-effective [11]. Other willingness-to-pay
thresholds included medical costs for a person infected with
HIV [62] and ‘‘a variety of formal and informal international
standards’’ [84]. The particular ICER compared to the chosen
willingness-to-pay threshold varied between studies and gross
national income was sometimes used in place of GDP.
The two countries for which the greatest numbers of
health economic evaluations have been conducted are India
and Thailand. Findings from evaluations conducted in these
countries further emphasize the message that targeted pro-
grammes are generally cost-effective whereas those aimed at
the general population are not cost-effective. In Figure 3, the
cost per infection averted divided by per capita GDP is shown
for evaluations of programmes conducted in (A) India and (B)
Thailand.
For India, non-targeted interventions or programmes
for the general public, including workplace programs, in-
formation, education and communication (IEC), microbi-
cide programmes for the public, mixed/tuberculosis (TB)/
unclear programs and programs for tuckers, street children,
prisoners and migrant labourers had an ICER/per capita
GDP ratio point estimate above 3. Some general popula-
tion programmes were more cost-effective, including youth-
based interventions, voluntary counselling and testing (VCT),
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sexually transmitted infection management (STI) and blood
banks. Programmes targeting SW and programmes for
PMTCT were deemed to be cost-effective in all evaluations.
Similarly for Thailand, interventions targeting the public and
mixed target groups have a wide range of ICER/per capita
GDP ratios; notably, the most common interventions of
condom distribution and education programmes for the
public and mixed target groups have relatively poor cost-
effectiveness. It was found that interventions targeting MSM
have an ICER/per capita GDP ratio of less than 2, as does
PMTCT in all but one evaluation. ART programmes were
deemed to have a high ICER/per capita GDP ratio.
A relatively large proportion of HIV prevention resources
are allocated to the general public or otherwise untargeted.
The allocation of prevention programme spending to differ-
ent target groups is given for 12 countries in Figure 4.
There is large variability in the proportions of resources
allocated to different target population groups. However,
greater than 30% of all HIV resources were provided for
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Figure 2. Point estimates and ranges for ICER divided by per capita GDP. Studies are included here if they reported ICER for an individual
country (or if this could be easily calculated), and if the ICER comparator was ‘‘no intervention’’ or ‘‘status quo.’’ Numbers in brackets at the
start of a label are the reference number; a name in brackets indicates that the study was received as a personal communication. Study
timeframes, where known, are given in brackets at the end of the label. Many studies gave multiple values for a particular ICER, representing
variations such as different coverage levels; all values are included in the figure. The ranges are those given in the studies; for the range
meaning, see the summary table (Supplementary file 3). For clarity, if a study gave a range but no point estimate, the point estimate was
considered to be the midpoint of the range. (A) ICER is cost per life-year saved. (B) ICER is cost per DALY saved. (C) ICER is cost per QALY
gained. (D) ICER is cost per HIV infection averted.
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countries and greater than 50% of HIV resources were non-
targeted in five countries (Figure 4).
Discussion
To determine whether actual spending on HIV interventions
is in accordance with the latest evidence of HIV intervention
cost-effectiveness, and also to address the lack of a recent
comprehensive review of such evidence from countries with
concentrated epidemics, we conducted a systematic review
of studies of cost-effectiveness of HIV interventions in Asia
and Eastern Europe.
Generally, we found that programmes targeting popula-
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Figure 3. Point estimates and ranges for cost per HIV infection averted divided by per capita GDP, where this could be established and
where the comparator was ‘‘no intervention’’ or ‘‘status quo,’’ for interventions in India (A) and Thailand (B). Study timeframes, where
known, are given in brackets. Many studies gave multiple values for a particular ICER, representing variations such as different coverage
levels; all values are included in the figure. The ranges are those given in the studies; for the range meaning, see the summary table
(Supplementary file 3). For clarity, if a study gave a range but no point estimate, the point estimate was considered to be the midpoint
of the range.
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cost-effective while programmes targeting the general public
were not cost-effective or much less cost-effective than
targeted programmes. However, for all target groups some
evaluated programmes reported low ICERs and others re-
ported high ICERs. Some programmes for the general popu-
lation, such as VCT and STI treatment programmes, were
shown to have greater cost-effectiveness (in India) than other
programmes for the general public. Although VCT and STI
programmes do target the public, their users will self-select
and be those who consider themselves to be at risk of
acquiring HIV or other STIs. Therefore, these more cost-
effective ‘‘general population’’ programmes are also targeted
towards those at greater risk. Conversely, workplace pro-
grammes, IEC and other non-targeted programmes are
somewhat indiscriminate in that they will cover many people
who are at low risk for HIV infection. This is likely to be the
main reason for these broader programmes’ lower cost-
effectiveness.
We also determined, through collation of data from
National AIDS Spending Assessments from twelve countries
in the region, that for eight of these countries, over 30% (and
as high as 72%) of prevention funding over recent years was
non-targeted and/or allocated to the general population
despite the evidence of the low cost-effectiveness of these
programmes and that more cost-effective programmes for
most at-risk populations are generally far from saturation
[41,130].
It could be considered that a priority is to guard the
general population from the entry of HIV that would
otherwise spark generalized epidemics as seen in Southern
Africa. However, there is little evidence of a generalized
epidemic occurring to date. The most at-risk populations of
PWID, SW and MSM are often marginalized and therefore it
may be politically difficult to invest significantly in health
interventions targeting them. However, the evidence collated
here suggests that decision makers would be wise to shift
the limited HIV/AIDS resources available away from general
population programmes and towards interventions that
specifically target groups of people at greatest risk of infec-
tion. The interventions implemented should be those that
have proven efficacy and are feasible in the given contexts. In
doing so, the investment has the potential to make the
greatest epidemiological impact and future economic return
on the given investment.
A recent study found that a trial of antiretroviral pre-
exposure prophylaxis (PrEP) given to PWID in Bangkok,
Thailand, reduced transmission of HIV by 48.9% [131]. We
have seen in this review that interventions targeting PWID
can be very cost-effective and so look forward to a cost-
effectiveness evaluation of PrEP for PWID. PrEP has also
reduced transmission by 44% in MSM [132], and so it may be
that PrEP becomes a key HIV intervention for many at-
risk sub-populations. A recent review of CEA of treatment
strategies for persons living with HIV/AIDS (PLWHA) found
that increasing access to ART was generally more cost-
effective than investing in more laboratory monitoring for
those on ART [133]. Most of the studies included in that
review considered Africa, but in those studies in our review
that assessed interventions that primarily target PLWHA,
ART seems to have been generally more cost-effective than
alternative PLWHA-targeted interventions (such as TB inter-
ventions); thus, our findings broadly agree.
Many studies (51 of 91) made their own assessment as to
whether an intervention was cost-effective or cost-saving.
We attempted to standardize comparison between studies
by reporting ICERs and ICERs/per capita GDP. The range of
outcome measures used (HIV infections averted, DALYs
averted, QALYs gained, life-years saved) further complicates
Figure 4. Allocation of 20072011 prevention programme spending by country and broad target population group. The ‘‘Other vulnerable’’
category includes programmes targeting unspecified MARPs.
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comparison. The most-reported of these indicators, cost per
HIV infection averted, is only reported by 43 of the 91
studies*less than half. There were also little-to-no simila-
rities in the way in which the different studies were carried out.
There is a lack of a standard in approaches to measuring effec-
tiveness, costing and assessing cost-effectiveness, as well as
in the time horizon over which analyses are conducted. The
lack of standardization has been highlighted in the literature
(e.g. [6] and [134]). The difference between assessing effec-
tiveness over one year and over a lifetime can be great, as is
the difference between including and excluding medical costs
that would have been incurred as the result of contracting
HIV, yet there were many such variations in the measure-
ment approaches used in the studies we reviewed. These
variations reduce the utility of comparing ICERs reported by
different studies and should be seriously considered when
interpreting the findings of this review. Indeed, such varia-
tions make it difficult for any attempt by decision makers to
evaluate and implement best evidence-based practice. That
all studies declared cost-effectiveness or found at least
one of the intervention components cost-effective may also
indicate bias in scientific approach or publication bias. To
reduce this potential, we recommend that a registry of CEA
protocols be established, similar to ClinicalTrials.gov [135]
for clinical trials, and results presented as per the protocol
regardless of the finding.
We recommend the adoption of a consistent costing and
reporting framework, to better enable the comparison of
the findings of different studies and to reduce the potential
for methods of measuring costs and benefits to be selec-
tively chosen in the interests of calculating a favourable
cost-effectiveness. Guidelines on clear calculation of cost-
effectiveness have existed for some time (e.g. [136139]) but
[140] noted that guidelines do not necessarily agree with one
another, and that their recommendations do not always
provide sufficient detail as to how they should be followed.
In addition, the emphasis generally seems to be on promot-
ing clarity (i.e. by being explicit about what has been
included and excluded in cost and benefit calculations) rather
than on proscribing what should be included and excluded.
Proscriptive guidelines would be more effective in creating
a consistent and comparable body of evaluation literature.
As a starting point for a proscriptive set of guidelines, we
recommend: healthcare costs saved be included when
costing; the ‘‘lifetime’’ timeframe (which was the most fre-
quently used in the studies in this review) be used; both
economic and financial costs be reported; costs and cost-
effectiveness ratios be reported in local currency, US$
(converted using standard exchange rates) and international
dollars; HIV infections averted (where this makes sense) and
QALYs gained be used as the measures of benefit; and point
estimates as well as 95% credible intervals be given for ICERs.
For all of these suggestions, there are arguments for using an
alternative measure or method, and discussion should be
made before guidelines are decided upon, but what we
consider important is not so much which particular method
is recommended in future guidelines, but simply that a
particular method is recommended.
Almost half of the studies included in this review were not
from peer-reviewed journal publications, and the results of
our quality assessment suggest that the standard of reporting
in peer-reviewed journal publications is higher. It should be
noted that there were many ambiguous cases for even
seemingly open-and-shut checklist items and so there was a
large degree of subjectivity involved in the assessment. Also,
the results are to a large extent a measure of how much
information was directly available to the reader, and so the
low rating of short documents, including conference abstracts
and posters, is unavoidable. Given the difference in rated
reporting quality of the peer-reviewed and grey literature, it is
important to note whether there is a noticeable difference in
their broad findings. Figure 2 identifies whether or not each
study shown was peer reviewed; we do not consider there to
be a clear pattern to the cost-effectiveness ratios based on
whether or not the source was peer reviewed, and so we
believe it is reasonable to draw conclusions by considering
together the peer-reviewed and grey literature.
This study has some limitations. The National AIDS Spend-
ing Assessments represented the best indication we could
find of actual spending on HIV interventions, but it should be
noted that spending categorized in Figure 4 as ‘‘not targeted’’
may have been targeted at high-risk groups. Also, our
exclusion of separate sensitivity/uncertainty analysis sections
reported within reviewed studies means that some informa-
tion that is in the literature was not included in our review.
Although we attempted to restrict study inclusion to one per
intervention, the high proportion of evaluations of future/
hypothetical interventions means that results of some studies
for the same region/country will probably have some overlap
with other evaluation studies.We did not include a restriction
on publication date in our inclusion criteria and, therefore,
some of the included studies are relatively old. Results from
these studies should be viewed with more caution because
the cost of some interventions may have changed (e.g. ART).
Furthermore, the epidemic dynamics from different time
periods, and in different country settings, may influence the
cost-effectiveness of interventions. Studies that compare
different intervention types and/or interventions in different
regions are valuable because they provide comparison of
those interventions without the usual concern about different
methods and settings, allowing for better dissemination of
knowledge and for general conclusions and principles to be
elicited, which can inform decision-making.
Most of the studies included (65 of 91) considered only
one relevant region/intervention combination. More studies
contrasting multiple regions and/or interventions would be
valuable. Of particular benefit might be more investigations
that contrast the cost-effectiveness of different interventions
targeting PWID, SW/clients, individuals living with HIV, and
the public. As can be seen in Table 1, several regions are
considered by only one study, while only interventions in
Thailand and India have each been considered in a relatively
large number of studies. There are also regions within Asia
and Eastern Europe not represented or under-represented in
the literature. There is also a lack of investigation into the
effectiveness and cost-effectiveness of programmes primarily
targeting MSM.
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With around one third of included studies evaluating in-
progress/completed evaluations, our results are dominated
by future/hypothetical studies that project estimated cost-
effectiveness of future programme implementation. Asses-
sing the potential cost-effectiveness of different budget
decisions and also evaluating interventions after implementa-
tion may provide greater rigor to the process of identifying
greatest value for money. However, in current environments
where decisions need to be made on resource prioritization,
our study suggests the greatest value for money, resulting in
largest epidemiological impact, will be attained by targeting
populations and sub-populations of people at greatest per
capita risk of infection. We suggest that less-targeted inter-
vention programmes should be considered only when these
groups are covered with programmes towards saturation.
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